TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00671736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moli1901
Description: 2,5 ml inhalation solution, 8 weeks treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moli1901
Description: 2,5 ml inhalation solution, 8 weeks treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moli1901
Description: 2,5 ml inhalation solution, 8 weeks treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moli1901 placebo
Description: 2,5 ml placebo solution, 8 weeks treatment period
Study: NCT00403377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
Study: NCT02237417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Oral antipsychotics
Description: A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM aripiprazole once monthly
Description: A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.

Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: A total of 15 healthy controls will participate in the study and will not receive medication
Study: NCT03140241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDR measurement
Description: PDR measurement at two standardized times perioperatively:~1. : anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~2. : administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth
Study: NCT03365271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drainage
Description: Applying a drain tube during TKA procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-drainage
Description: No drain tube will be applied during TKA procedure
Study: NCT03745612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
Study: NCT00587522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NDO Full-thickness Plicator
Description: The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
Study: NCT01295814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inactive drug
Description: 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Study: NCT06176079

Intervention type: DRUG
Intervention: Hyperpolarized (HP) 13C
Description: A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.

Intervention type: DRUG
Intervention: Hyperpolarized (HP) 13C
Description: A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.

Intervention type: DRUG
Intervention: Hyperpolarized (HP) 13C
Description: A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.

Intervention type: DRUG
Intervention: Hyperpolarized (HP) 13C
Description: A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.

Intervention type: DRUG
Intervention: Hyperpolarized 13C-Urea
Description: Given intravenously (IV)

Intervention type: DRUG
Intervention: Hyperpolarized 13C-Urea
Description: Given intravenously (IV)

Intervention type: DRUG
Intervention: Hyperpolarized 13C-Urea
Description: Given intravenously (IV)

Intervention type: DRUG
Intervention: Hyperpolarized 13C-Urea
Description: Given intravenously (IV)

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging procedure

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging procedure

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging procedure

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging procedure

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging procedure

Intervention type: PROCEDURE
Intervention: Saline Flush
Description: A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C

Intervention type: PROCEDURE
Intervention: Saline Flush
Description: A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C

Intervention type: PROCEDURE
Intervention: Saline Flush
Description: A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C

Intervention type: PROCEDURE
Intervention: Saline Flush
Description: A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
Study: NCT00758667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
Study: NCT01546610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insoles intervention
Description: EVA insole with arch support and bar retrocapital

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo insole
Description: EVA insole flat
Study: NCT02984813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlaucoHealth
Description: Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlaucoSelect
Description: Containing curcumin, bilberry extract, and grape seed extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredients
Study: NCT01256788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euflexxa
Description: 4 injections of 2ml of Euflexxa

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 4 injections of 3 ml of sterile saline
Study: NCT01203202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomipramine
Description: 15mg and 30mg on demand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomipramine
Description: 15mg and 30mg on demand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomipramine
Description: 15mg and 30mg on demand
Study: NCT03574584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0165-1562
Description: Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0165-1562
Description: Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0165-1562)
Description: Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0165-1562)
Description: Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
Study: NCT01217957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study: NCT02074553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F03 (Reference)
Description: Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F03 (Reference)
Description: Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F03 (Reference)
Description: Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F03 (Reference)
Description: Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F07 (Test)
Description: Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F07 (Test)
Description: Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F07 (Test)
Description: Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F07 (Test)
Description: Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F08 (Test)
Description: Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
Study: NCT04165577

Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS
Description: 1-Hz rTMS targeting frontal pole

Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS
Description: 1-Hz rTMS targeting frontal pole

Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS
Description: 1-Hz rTMS targeting frontal pole

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 1-Hz rTMS targeting frontal pole
Study: NCT02074553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F08 (Test)
Description: Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F08 (Test)
Description: Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F08 (Test)
Description: Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F14 (Test)
Description: Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F14 (Test)
Description: Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F14 (Test)
Description: Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F14 (Test)
Description: Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
Study: NCT00500162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tri-Luma Maintenance regimen

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tri-Luma Maintenance regimen
Study: NCT01487408

Intervention type: DRUG
Intervention: insulin aspart
Description: Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
Study: NCT00367887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron
Description: SC injection, weight based dosing, weekly, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REBETOL
Description: Capsules, weight based dosing, Q12 hrs daily, 48weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCV 796
Description: Capsules, 500 mg, Q 12 hrs. daily, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron
Description: SC injection, weight based dosing, weekly, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REBETOL
Description: Capsules, weight based dosing, Q12 hrs daily, 48weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCV 796
Description: Capsules, 500 mg, Q 12 hrs. daily, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron
Description: SC injection, weight based dosing, weekly, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REBETOL
Description: Capsules, weight based dosing, Q12 hrs daily, 48weeks
Study: NCT02486133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prezista
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prezista
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norvir
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvir
Description: once daily
Study: NCT04165577

Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS
Description: 1-Hz rTMS targeting frontal pole

Intervention type: DEVICE
Group type: OTHER
Intervention: sham rTMS
Description: sham rTMS targeting frontal pole

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS targeting frontal pole
Study: NCT02785549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 600 mg/8hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 600 mg/8hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g/8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g/8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Description: 875mg/125mg/8 hours
Study: NCT02486133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivicay
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: once daily
Study: NCT01047358

Intervention type: DRUG
Intervention: Aromasin
Description: 25 mg table QD

Intervention type: DRUG
Intervention: Aromasin
Description: 25 mg table QD
Study: NCT00948376

Intervention type: GENETIC
Intervention: IFT80 screening
Description: Natural History

Intervention type: GENETIC
Intervention: IFT80 screening
Description: Natural History
Study: NCT02746653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TroClose1200(TM)
Description: Creation of access port and closure it by the same device, TroClose1200(TM)
Study: NCT02252003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scales testing
Study: NCT03258385

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 fortified UHT milk
Description: Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain UHT milk
Description: Daily intake of 200 mL of plain UHT milk
Study: NCT02303496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Cream
Description: Cream Containing Platelet Rich Plasma and Oleaginous Base

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Sterile Water Cream
Description: Cream Containing Sterile Water and Oleaginous Base
Study: NCT00696072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg once daily, up to 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Tablets, Oral, 2.5 mg, once daily, up to 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Tablets, Oral, 2.5 mg, once daily, up to 2 years
Study: NCT00000385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium 600 mg to 2700 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02486133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kivexa
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Descovy
Description: once daily
Study: NCT03130803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insufficient Sleep
Description: 2 days with 5 hour sleep opportunity per day
Study: NCT00967746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel-releasing IUS
Description: Low dose; treatment duration of 6 months with a possible extension to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel-releasing IUS
Description: Intermediate dose; treatment duration of 6 months with a possible extension to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel-releasing IUS
Description: High dose; treatment duration of 6 months with a possible extension to 12 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiload-cu 375®
Description: Duration of 6 months with a possible extension to 12 months
Study: NCT02437344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581aa
Description: 92 minute infusion of CI-581aa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone titration and XR-NTX initiation
Description: participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
Study: NCT00390143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine 134612
Description: One intramuscular dose during the primary study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One subcutaneous dose during the primary study